Welcome to Scholar Publishing Group

International Journal of World Medicine, 2023, 4(3); doi: 10.38007/IJWM.2023.040309.

Research Progress on Pathogenesis of Melasma


Guo Ru, Xiaoning Yan

Corresponding Author:
Xiaoning Yan

Shaanxi Provincial Hospital of Chinese Medicine, Xi'an 710003, Shaanxi, China


Melasma is a common facial symmetrical pigmentation skin disease, which occurs in women of childbearing age and seriously affects the appearance and quality of life of female patients. At present, the etiology and pathogenesis of melasma have not been fully elucidated. In recent years, many studies have shown that ultraviolet radiation, hormone levels, genetic factors, inflammatory reactions, free radicals and skin microbial factors play an important role in the pathogenesis of melasma. This article reviews the research progress of the pathogenesis of melasma in order to better prevent and treat melasma in clinic.


Melasma, The etiology, Pathogenesis, Research Progress

Cite This Paper

Guo Ru, Xiaoning Yan. Research Progress on Pathogenesis of Melasma. International Journal of World Medicine (2023), Vol. 4, Issue 3: 71-78. https://doi.org/10.38007/IJWM.2023.040309.


[1] Miot LD, Miot HA, Polettini J, et al. Morphologic changes and the expression of alpha-melanocyte stimulating hormone and melanocortin-1 receptor in melasma lesions: a comparative study. Am J Dermatopathol, 2010, 32(7):676-682.

[2] Kim N H, Lee A Y. Histamine effect on melanocyte pro-liferation and vitiliginous keratinocyte survival. ExpDermatol. 2010, 19(12), 1073-1079. 

[3] Filoni A, Mariano M, Cameli N. Melasma: How hormones can modulate skin pigmentation. J Cosmet Dermatol, 2019, 18(2):458-463. 

[4] Handel A C, Miot L D, Miot H A. Melasma: a clinicaland epidemiological review. An Bras Dermatol, 2014, 89(5):771-782. 

[5] Holmo NF, Ramos GB, Salomao H, et al. Complex segregation analysis of facial melasma in Brazil: evidence for a genetic susceptibility with a dominant pattern of segregation. Arch Dermatol Res, 2018, 10(310):827-831. 

[6] Handel AC, Lima PB, Tonolli VM, et al. Risk factors for facial melasma in women: A case-control study. Br J Dermatol, 2014, 171(3):588-594. 

[7] SarkarR, Puri P, JainRK, et al. Melasma in men: aclinical, aetiological and histological study. J EurAcad Dermatol Venereol, 2010, 24(7):768-772. 

[8] Zhang Haixia, Liang Nailong. Study on correlation between melasma and tyrosinase activity. Journal of Liaoning University of Traditional Chinese Medicine, 2010, 12(9):99-100. 

[9] Cai Hongwei, Ji Qing, Xiang Yun, et al. Therapeutic effect of tranexamic acid tablets combined with Q-switched YAG laser on chloasma. Journal of Dermatology and venereology, 2012, 19(2):94-95. 

[10] VIdeira I F, Mourad F, Magina S. Mechanisms reg-ulating melanogenesis. An Bras Dermatol, 2013, 88(1):76-83. 

[11] Sarkar R, Ailawadi P, Garg S, Melasma in Men: A Review of Clinical, Etiological, and Management Issues. J Clin Aesthet Dermatol, 2018, 11(2):53-59. 

[12] Rostami Mogaddam M, Lranparvar Alamdarim, Maleki N, et al. Evaluation of autoimmune thyroiddisease in melasma. J Cosmet Dermat, 2015, 14(2):167-171. 

[13] Kang HY, Suzuki I, Lee DJ, et al. Transcriptional profiling showsaltered expression of wnt pathway-and lipid metabolism-relatedgenes as well as melanogenesis-related genes in melasma. J InvestDermatol, 2011, 131: 1 692-1 700. 

[14] Piao MJ, Zhang R, Lee NH, et al. Protective effect of triphlorethol-A against ultraviolet B-mediated damage of human keratinocytes. J Photochem Photobiol B, 2012, 5, 106: 74-80. 

[15] Espósito Acc, Brianezi G, De Souza NP, et al. Exploring pathways for sustained melanogenesis in facial melasma:an immunofluorescence study. Int J Cosmet Sci, 2018, 40(4): 420-424

[16] Rodriguez-Arambula, Adriana, Pablo Castanedo-Cazares, Juan, Fuentes-Ahumada, Cornelia, et al. CD4, IL-17, and COX-2 Are Associated With Subclinical Inflammation in Malar Melasma. American Journal of Dermatopathology. 2015, 37(10). 

[17] Wang Yin-Juan, GU Hua, Guo Meihua, et al. Expression of toll-like receptors 2 and 4 in skin lesions and blood of patients with melasma. Chinese Journal of Dermatology, 2015, 48(2): 100-103. (in Chinese).

[18] Kim EH, Kim YC, Lee ES, et al. The vascular characteristics ofmelasma. J Dermatol Sci, 2007, 46:111-116. 

[19] Shi Yue, TAN Cheng. Research progress on pathogenesis of melasma. Chinese Journal of Integrated Traditional and Western Medicine Dermatology and Venereology, 2016, 15(1):55-58.

[20] Zhang Guodong, Zhou Pei. Pathogenesis and treatment of melasma. Fujian Journal of Medicine, 2015, 37(1):128-130. 

[21] Iraji F, Nasimi M, Asilian A, et al. Efficacy ofmesotherapy with tranexamic acid and ascorbic acidwith and without glutathione in treatment of melasma: a split face comparative trial. J Cosmet Dermatol, 2019, 1(85): 1416-1421.

[22] Kim S J, Park J Y, Shibata T, et al. Efficacy and pos-sible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol, 2016, 41(5):480-485. 

[23] Choi YK, Rho YK, Yoo KH, et al. Effects of vitamin C vs. multivitamin on melanogenesis:comparative study in vitroand in vivo. Int J Dermatol, 2010, 49(2):218-226. 

[24] Starner Rj, Mc Clelland L, Abdel-Malek Z, et al. PGE2 is a UVR-inducible autocrine factor for humanmelanocytes that stimulates tyrosinase activation. Experimental Dermatology, 2010, 19(7):682-684. 

[25] Ulan Toya. Li Rui Ya. Study on pathogenesis of melasma. Inner Mongolia Medical Journal, 2018, 50(11):1299-1301. (in Chinese).

[26] Han Xiuping. Application of tea polyphenols combined with photon technology in the treatment of chloasma. Medical Information, 2010, 23(3):649-650. 

[27] Xue Mei, Tang Haiyan, Wang Zuhong, et al. Research progress on pathogenesis of melasma. Chinese Journal of Medical Cosmetology, 2013, 3(4):73-74, 61. (in Chinese).